{"title":"Peptide Blends","description":"\u003cp\u003ePeptide blends combine two or more research compounds in a single vial, which cuts down on the number of vials to reconstitute and track. Optic Labs supplies blends in Australia, each third-party HPLC tested with Certificates of Analysis published in our \u003ca href=\"\/pages\/labreport\"\u003eCOA library\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch2\u003eBlends available\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/klow80-bpc-157-10mg-ghk-cu-50mg-tb-500-10mg-kpv-10mg\"\u003eKLOW80\u003c\/a\u003e: BPC-157 10mg, GHK-Cu 50mg, TB-500 10mg and KPV 10mg\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/glow70-bpc-157-10mg-ghk-cu-50mg-tb-500-10mg\"\u003eGLOW70\u003c\/a\u003e: BPC-157 10mg, GHK-Cu 50mg and TB-500 10mg\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/bpc-157-tb-500-10mg-20mg\"\u003eBPC-157 + TB-500\u003c\/a\u003e: 10mg and 20mg combined vials\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/cjc-1295-no-dac-ipamorelin-10mg\"\u003eCJC-1295 (no DAC) + Ipamorelin\u003c\/a\u003e: 10mg combined vial\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a side-by-side look at the KLOW and GLOW formulations, see our \u003ca href=\"\/blogs\/news\/klow-peptide-blend-australia-research-guide\"\u003eKLOW peptide blend research guide\u003c\/a\u003e and \u003ca href=\"\/blogs\/news\/bpc-157-tb-500-stack-research-guide\"\u003eBPC-157 + TB-500 guide\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch2\u003eReconstitution\u003c\/h2\u003e\n\u003cp\u003eBlends are supplied lyophilised and are reconstituted with \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e. Our free \u003ca href=\"\/pages\/peptide-calculator\"\u003epeptide calculator\u003c\/a\u003e handles the concentration maths for each component.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eAll products are supplied for laboratory research use only and are not for human consumption.\u003c\/em\u003e\u003c\/p\u003e","products":[{"product_id":"bpc-157-tb-500-10mg-20mg","title":"BPC-157 + TB-500 10mg \/ 20mg","description":"\u003cp\u003e\u003cstrong\u003eBuy high-purity BPC-157 + TB-500 blend in Australia (10mg \/ 20mg). Third-party lab tested at \u0026gt;99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhat is BPC-157 + TB-500?\u003c\/strong\u003e This is a single vial that combines two repair-focused research peptides — BPC-157, a stable gastric-derived pentadecapeptide, and TB-500, an actin-binding fragment of thymosin β-4. Laboratories study the pair together in connective-tissue, tendon, gut and cardiovascular injury models to compare how their complementary repair pathways interact. Optic Labs supplies HPLC-tested BPC-157 + TB-500 (\u0026gt;99% purity) as a co-lyophilised 10mg or 20mg vial for laboratory research use only, dispatched Australia-wide from Sydney.\u003c\/p\u003e\n\n\u003ch2\u003eAbout the BPC-157 + TB-500 blend\u003c\/h2\u003e\n\u003cp\u003eThe BPC-157 + TB-500 blend pairs two of the most extensively studied research peptides in tissue-repair and regenerative biology in a single lyophilised vial. BPC-157, a stable 15-amino-acid pentadecapeptide derived from a fragment of human gastric juice protein BPC, has been characterised in published research for its effects on angiogenesis, growth-factor signalling and connective-tissue repair across a wide range of injury models. TB-500 is a synthetic 17-amino-acid fragment of thymosin β-4 (Tβ4) corresponding to the actin-binding region, studied for its effects on cell migration, actin remodelling and microvascular development. Combined in equal-mass ratios, the blend is a frequently chosen tool in animal-model research where complementary repair pathways are examined in parallel.\u003c\/p\u003e\n\u003cp\u003eOptic Labs supplies the BPC-157 + TB-500 blend in Australia as a co-lyophilised powder in two formats — 10mg total (5mg BPC-157 + 5mg TB-500) and 20mg total (10mg BPC-157 + 10mg TB-500) — third-party HPLC verified at \u0026gt;99% purity for both peptides. The blend is supplied strictly for laboratory research use only and is not intended for human consumption, clinical, cosmetic, diagnostic or veterinary application.\u003c\/p\u003e\n\n\u003ch2\u003eProduct specifications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompound:\u003c\/strong\u003e BPC-157 + TB-500 co-lyophilised blend\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBPC-157 CAS:\u003c\/strong\u003e 137525-51-0  |  \u003cstrong\u003eTB-500 CAS:\u003c\/strong\u003e 77591-33-4\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBPC-157 sequence:\u003c\/strong\u003e Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (pentadecapeptide, ~1419.5 g\/mol)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTB-500 sequence:\u003c\/strong\u003e Ac-LKKTETQ (active fragment of thymosin β-4 17-mer, ~889.0 g\/mol; full TB-500 17-mer ~1894.2 g\/mol depending on supplier definition)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder (co-formulated)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% by HPLC for each peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAvailable sizes:\u003c\/strong\u003e 10mg total (5mg + 5mg) and 20mg total (10mg + 10mg)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrigin:\u003c\/strong\u003e Manufactured to research-grade specifications, third-party HPLC verified\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShipping:\u003c\/strong\u003e Australia-wide domestic dispatch from Sydney, NSW\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eResearch background\u003c\/h2\u003e\n\u003cp\u003eBPC-157 and TB-500 are often co-studied because their published mechanisms operate on complementary axes of tissue repair — BPC-157 on angiogenic, nitric-oxide and growth-factor pathways; TB-500 on actin sequestration, cell migration and microvasculature. Researchers combine them to probe whether parallel pathway engagement produces additive or distinct effects in connective-tissue, gastrointestinal and cardiovascular injury models.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBPC-157: tendon-to-bone and ligament-healing models examining fibroblast proliferation and outgrowth in rats and rabbits.\u003c\/li\u003e\n\u003cli\u003eBPC-157: gastrointestinal-protection research in models of ulcerative damage, inflammatory bowel disease and short-bowel syndrome.\u003c\/li\u003e\n\u003cli\u003eBPC-157: angiogenic and VEGF\/eNOS pathway signalling in wound and vascular research.\u003c\/li\u003e\n\u003cli\u003eTB-500: G-actin sequestration and actin-cytoskeleton remodelling in cell-migration assays.\u003c\/li\u003e\n\u003cli\u003eTB-500: cardiac-repair models examining epicardial cell activation and capillary density post-infarction.\u003c\/li\u003e\n\u003cli\u003eTB-500: corneal, dermal and hair-follicle research examining keratinocyte and endothelial migration.\u003c\/li\u003e\n\u003cli\u003eCombined in-vivo studies in rodent musculoskeletal-injury models examining whether co-administration alters repair time-course versus single-peptide arms.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor deeper background on each peptide, see our \u003ca href=\"\/blogs\/news\/bpc-157-tb-500-stack-research-guide\"\u003eBPC-157 + TB-500 stack research guide\u003c\/a\u003e, our \u003ca href=\"\/blogs\/news\/bpc-157-complete-research-guide-2025\"\u003eBPC-157 complete research guide\u003c\/a\u003e and our \u003ca href=\"\/blogs\/news\/tb-500-australia-thymosin-injury-research-guide\"\u003eTB-500 thymosin β-4 research guide\u003c\/a\u003e. Researchers working with reconstitution should also reference our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003epeptide reconstitution guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eReconstitution and handling\u003c\/h2\u003e\n\u003cp\u003eThe blend is supplied co-lyophilised, meaning both peptides are dissolved together when the vial is reconstituted. Use sterile \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e. For the 10mg blend (5mg + 5mg), adding 2mL of bacteriostatic water yields 2.5mg\/mL of each peptide (5mg\/mL total peptide); 1mL gives 5mg\/mL of each (10mg\/mL total). For the 20mg blend (10mg + 10mg), 2mL of bacteriostatic water gives 5mg\/mL of each peptide (10mg\/mL total). Add diluent slowly down the side of the vial — do not inject directly onto the lyophilised cake — and allow the powder to dissolve without vigorous shaking. Reconstituted blend should be stored at 2–8°C, protected from light, and used within 30 days. For worked dilution examples for any vial size, see our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003epeptide reconstitution calculator guide\u003c\/a\u003e and our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eCommonly stacked research peptides\u003c\/h2\u003e\n\u003cp\u003eThe BPC-157 + TB-500 blend sits at the centre of the broader tissue-repair and regenerative-research family. Researchers studying related repair pathways often hold the constituent peptides on hand individually, alongside connective-tissue and anti-inflammatory tools:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/bpc-157\"\u003eBPC-157\u003c\/a\u003e — single-compound vial for protocols that require BPC-157 alone or at a non-1:1 ratio to TB-500.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/tb-500\"\u003eTB-500\u003c\/a\u003e — single-compound vial for protocols that require TB-500 alone.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/ghk-cu-50mg-100mg\"\u003eGHK-Cu\u003c\/a\u003e — copper-binding tripeptide studied in collagen synthesis, dermal repair and angiogenesis research.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/kpv-10mg\"\u003eKPV\u003c\/a\u003e — α-MSH-derived tripeptide examined in anti-inflammatory and gut-barrier research, often run alongside repair stacks.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/glow70-bpc-157-10mg-ghk-cu-50mg-tb-500-10mg\"\u003eGLOW70 stack\u003c\/a\u003e — pre-blended BPC-157 + GHK-Cu + TB-500 for researchers needing a three-compound combination.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor broader stack-design context, see our \u003ca href=\"\/blogs\/news\/peptide-research-stacks-australia-combinations\"\u003epeptide research stacks overview\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently asked questions\u003c\/h2\u003e\n\n\u003ch3\u003eIs the BPC-157 + TB-500 blend legal in Australia?\u003c\/h3\u003e\n\u003cp\u003eNeither BPC-157 nor TB-500 is an approved therapeutic good in Australia, and neither peptide is registered with the Therapeutic Goods Administration (TGA). Optic Labs supplies the blend strictly for laboratory research, development and analytical use — not for human consumption, clinical or cosmetic application. For a detailed overview of how research peptides sit within the Australian regulatory framework, see our \u003ca href=\"\/blogs\/news\/are-peptides-legal-australia-tga-compliance-2025\"\u003eguide to peptide legality and TGA compliance in Australia\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is the BPC-157 + TB-500 blend?\u003c\/h3\u003e\n\u003cp\u003eIt is a co-lyophilised vial containing equal masses of BPC-157 (a pentadecapeptide derived from gastric juice protein BPC) and TB-500 (a fragment of thymosin β-4). The two peptides are widely studied together in tissue-repair, gastrointestinal and cardiovascular injury models. For background on each, see our \u003ca href=\"\/blogs\/news\/bpc-157-tb-500-stack-research-guide\"\u003eBPC-157 + TB-500 stack research guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhy use a blend instead of running BPC-157 and TB-500 from separate vials?\u003c\/h3\u003e\n\u003cp\u003eA co-lyophilised blend reduces handling steps and the number of reconstitution events, which is convenient when a research protocol consistently uses the two peptides at a 1:1 mass ratio. For protocols that require unequal ratios, dose-escalation across one peptide while holding the other constant, or single-peptide arms, separate \u003ca href=\"\/products\/bpc-157\"\u003eBPC-157\u003c\/a\u003e and \u003ca href=\"\/products\/tb-500\"\u003eTB-500\u003c\/a\u003e vials are the appropriate choice.\u003c\/p\u003e\n\n\u003ch3\u003eHow much bacteriostatic water do I mix with a BPC-157 + TB-500 vial?\u003c\/h3\u003e\n\u003cp\u003eFor the 10mg blend (5mg BPC-157 + 5mg TB-500), 2mL of \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e gives 2.5mg\/mL of each peptide. For the 20mg blend (10mg + 10mg), 2mL gives 5mg\/mL of each. See our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003ereconstitution calculator guide\u003c\/a\u003e for additional worked examples.\u003c\/p\u003e\n\n\u003ch3\u003eHow should the reconstituted blend be stored?\u003c\/h3\u003e\n\u003cp\u003eReconstituted blend should be stored at 2–8°C, protected from light, and used within 30 days. Lyophilised vials are stable at 2–8°C until reconstitution. For full handling guidance, see our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage research guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhere does Optic Labs ship to?\u003c\/h3\u003e\n\u003cp\u003eOptic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.\u003c\/p\u003e\n\n\u003ch2\u003eLegal disclaimer\u003c\/h2\u003e\n\u003cp\u003eAll products on this site are supplied for \u003cstrong\u003elaboratory research, development or analytical use only\u003c\/strong\u003e. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the \u003cstrong\u003eTherapeutic Goods Administration (TGA)\u003c\/strong\u003e or the \u003cstrong\u003eAPVMA\u003c\/strong\u003e and are not intended to diagnose, treat, cure or prevent any disease. Optic Labs is not a \u003cstrong\u003ecompounding pharmacy\u003c\/strong\u003e or manufacturing facility as defined under the \u003cem\u003eTherapeutic Goods Act 1989\u003c\/em\u003e, and is not a registered provider of scheduled medicines or therapeutic goods.\u003c\/p\u003e","brand":"Optic Labs","offers":[{"title":"10mg","offer_id":51430831489249,"sku":null,"price":94.99,"currency_code":"AUD","in_stock":true},{"title":"20mg","offer_id":51430831522017,"sku":null,"price":132.99,"currency_code":"AUD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0867\/4076\/2849\/files\/wolf10.png?v=1794295902"},{"product_id":"cjc-1295-no-dac-ipamorelin-10mg","title":"CJC-1295 no DAC + Ipamorelin 10mg","description":"\u003cp\u003e\u003cstrong\u003eBuy high-purity CJC-1295 + Ipamorelin blend (10mg) in Australia. Third-party lab tested at \u0026gt;99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhat is CJC-1295 + Ipamorelin?\u003c\/strong\u003e This blend combines a GHRH-receptor peptide (CJC-1295 no-DAC) with a selective ghrelin-receptor peptide (Ipamorelin), two different triggers of the body's own growth-hormone pulses. Endocrinology laboratories use the pair as a tool to study maximal GH and IGF-1 release, body-composition models, sleep architecture, and tissue-recovery pathways. Optic Labs supplies HPLC-tested CJC-1295 + Ipamorelin (\u0026gt;99% purity) as a co-lyophilised 10mg vial for laboratory research use only, dispatched Australia-wide from Sydney.\u003c\/p\u003e\n\n\u003ch2\u003eAbout CJC-1295 + Ipamorelin\u003c\/h2\u003e\n\u003cp\u003eCJC-1295 (no-DAC) and ipamorelin are two complementary growth-hormone-axis research peptides that are frequently co-studied as a blend. CJC-1295 (no-DAC), also known as Mod GRF 1-29, is a tetrasubstituted analogue of growth-hormone-releasing hormone (GHRH 1-29) that binds the GHRH receptor on somatotrophs of the anterior pituitary. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist — a pentapeptide growth hormone secretagogue. In published endocrinology research, the two peptides act on distinct but complementary pathways: GHRH-receptor activation increases the amplitude of natural GH pulses, while a selective GH secretagogue can synergistically increase pulse frequency.\u003c\/p\u003e\n\u003cp\u003eOptic Labs supplies CJC-1295 (no-DAC) and ipamorelin as a co-lyophilised research blend at 10mg total fill (5mg CJC-1295 + 5mg ipamorelin), third-party HPLC tested to \u0026gt;99% purity for each component. The product is distributed Australian-domestic from Sydney, NSW, for in vitro and laboratory research applications. The blend is supplied strictly for laboratory research, development or analytical use and is not intended for human consumption.\u003c\/p\u003e\n\n\u003ch2\u003eProduct specifications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompound:\u003c\/strong\u003e CJC-1295 (no-DAC, also known as Mod GRF 1-29) co-lyophilised with ipamorelin\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCAS numbers:\u003c\/strong\u003e CJC-1295 (no-DAC): 863288-34-0; ipamorelin: 170851-70-4\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular formula:\u003c\/strong\u003e CJC-1295 (no-DAC): C\u003csub\u003e152\u003c\/sub\u003eH\u003csub\u003e252\u003c\/sub\u003eN\u003csub\u003e44\u003c\/sub\u003eO\u003csub\u003e42\u003c\/sub\u003e; ipamorelin: C\u003csub\u003e38\u003c\/sub\u003eH\u003csub\u003e49\u003c\/sub\u003eN\u003csub\u003e9\u003c\/sub\u003eO\u003csub\u003e5\u003c\/sub\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e CJC-1295 (no-DAC): ~3367.9 g\/mol; ipamorelin: ~711.85 g\/mol\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSequence (CJC-1295 no-DAC):\u003c\/strong\u003e Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSequence (ipamorelin):\u003c\/strong\u003e Aib-His-D-2-Nal-D-Phe-Lys-NH\u003csub\u003e2\u003c\/sub\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder (combined fill)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% by HPLC for each component\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAvailable size:\u003c\/strong\u003e 10mg total (5mg CJC-1295 no-DAC + 5mg ipamorelin)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrigin:\u003c\/strong\u003e Manufactured to research-grade specifications, third-party HPLC verified\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShipping:\u003c\/strong\u003e Australia-wide domestic dispatch from Sydney, NSW\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eResearch background\u003c\/h2\u003e\n\u003cp\u003eCJC-1295 (no-DAC) was developed by ConjuChem in the early 2000s as a stabilised GHRH analogue, with four amino-acid substitutions to the native GHRH 1-29 sequence that resist proteolytic degradation. The \"no-DAC\" variant lacks the drug affinity complex linker present on the longer-acting CJC-1295 with DAC, giving it a shorter functional duration that more closely matches natural GH pulse kinetics. Ipamorelin was developed by Novo Nordisk as a selective GHS-R1a agonist designed to stimulate GH release without significant cortisol or prolactin responses, in contrast to earlier ghrelin-receptor agonists such as GHRP-6 and GHRP-2.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDual-pathway GH stimulation:\u003c\/strong\u003e in published endocrinology research, GHRH-receptor agonism (CJC-1295) and ghrelin-receptor agonism (ipamorelin) act through complementary intracellular pathways, with the combination producing larger GH pulses than either alone in animal model and isolated pituitary cell research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePulsatile release pattern:\u003c\/strong\u003e in animal models, the no-DAC variant of CJC-1295 has been studied for its capacity to amplify GH pulses while preserving the natural pulsatile pattern, distinguishing it from continuous-exposure GH-axis research compounds.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelectivity profile (ipamorelin):\u003c\/strong\u003e in receptor-binding and rodent endocrine studies, ipamorelin showed minimal stimulation of cortisol, prolactin or aldosterone, distinguishing it from non-selective GHS such as GHRP-6.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIGF-1 axis:\u003c\/strong\u003e in animal model research, GH-axis stimulation by CJC-1295 + ipamorelin has been associated with downstream increases in IGF-1, the principal mediator of many of GH's tissue effects.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBody composition models:\u003c\/strong\u003e in rodent research, GH-axis stimulation has been studied in connection with adipose tissue lipolysis and lean mass parameters.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSleep architecture research:\u003c\/strong\u003e in published research, GH-axis activity is closely tied to slow-wave sleep, and GH-secretagogue research peptides have been studied in models of sleep architecture.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRecovery and tissue research:\u003c\/strong\u003e GH\/IGF-1 axis activity is studied in animal model research on connective tissue, bone metabolism and post-injury recovery.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a more detailed research summary, see our \u003ca href=\"\/blogs\/news\/cjc-1295-ipamorelin-growth-hormone-stack-guide\"\u003eCJC-1295 + ipamorelin GH stack research guide\u003c\/a\u003e and our \u003ca href=\"\/blogs\/news\/what-are-peptides-australia-explainer\"\u003ewhat are peptides explainer\u003c\/a\u003e. Researchers working with reconstitution should also reference our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003epeptide reconstitution guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eReconstitution and handling\u003c\/h2\u003e\n\u003cp\u003eThe combined 10mg vial reconstitutes readily in \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e. A common laboratory approach is reconstitution in 2ml to yield a 5mg\/ml total working stock (corresponding to 2.5mg\/ml CJC-1295 + 2.5mg\/ml ipamorelin), or in 5ml for a 2mg\/ml total stock (1mg\/ml of each component). The bacteriostatic water should be drawn into a sterile syringe and injected slowly down the inside wall of the lyophilised vial, with the peptide cake allowed to dissolve passively rather than through agitation. Reconstituted blend should be aliquoted, refrigerated at 2–8°C and protected from light, with research stocks typically used within 30 days. For dilution maths across alternative volumes, see our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003ereconstitution calculator guide\u003c\/a\u003e. For long-term storage protocols, see our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eCommonly stacked research peptides\u003c\/h2\u003e\n\u003cp\u003eIn published research and laboratory protocols, CJC-1295 + ipamorelin is often co-investigated alongside other recovery, body-composition and longevity research peptides:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/bpc-157\"\u003eBPC-157\u003c\/a\u003e — pentadecapeptide co-investigated with GH-axis research peptides in tissue-repair and recovery models.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/tb-500\"\u003eTB-500\u003c\/a\u003e — Thymosin β4 fragment commonly examined alongside GH-axis stimulation in injury and recovery research.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/tesamorelin-10mg\"\u003eTesamorelin\u003c\/a\u003e — alternative GHRH analogue studied in body composition and visceral adipose tissue research.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/sermorelin-10mg\"\u003eSermorelin\u003c\/a\u003e — shorter GHRH 1-29 analogue investigated in endocrine research as an alternative GHRH-axis compound.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/nad-1000mg\"\u003eNAD+\u003c\/a\u003e — co-investigated alongside GH-axis research compounds in longevity and mitochondrial study designs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor broader context on combined research designs, see our \u003ca href=\"\/blogs\/news\/peptide-research-stacks-australia-combinations\"\u003epeptide research stacks overview\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently asked questions\u003c\/h2\u003e\n\n\u003ch3\u003eIs CJC-1295 + ipamorelin legal in Australia?\u003c\/h3\u003e\n\u003cp\u003eCJC-1295 and ipamorelin are not registered therapeutic goods in Australia, and growth-hormone-releasing peptides are subject to specific regulatory oversight by the Therapeutic Goods Administration. Optic Labs supplies the CJC-1295 + ipamorelin blend strictly for laboratory, research and analytical use only, not as a therapeutic good. For a full overview of how the TGA treats research peptides in Australia, see our \u003ca href=\"\/blogs\/news\/are-peptides-legal-australia-tga-compliance-2025\"\u003epeptide legality and TGA compliance guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is CJC-1295 + ipamorelin?\u003c\/h3\u003e\n\u003cp\u003eCJC-1295 (no-DAC) is a stabilised GHRH 1-29 analogue that activates the GHRH receptor; ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. The two are co-supplied as a research blend because they activate complementary pathways of GH release in published endocrinology research. For a research-level summary, see our \u003ca href=\"\/blogs\/news\/cjc-1295-ipamorelin-growth-hormone-stack-guide\"\u003eCJC-1295 + ipamorelin research guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is the difference between CJC-1295 with DAC and CJC-1295 without DAC?\u003c\/h3\u003e\n\u003cp\u003eThe \"DAC\" (drug affinity complex) is a maleimide linker that binds CJC-1295 to serum albumin, extending its functional half-life from hours to several days. CJC-1295 with DAC produces sustained GHRH-receptor exposure, while CJC-1295 no-DAC (Mod GRF 1-29) produces shorter pulses that more closely resemble the natural pulsatile pattern of GH release. Optic Labs supplies the no-DAC variant in this blend, which is the variant most commonly co-investigated with ipamorelin in published research.\u003c\/p\u003e\n\n\u003ch3\u003eWhy are CJC-1295 and ipamorelin commonly studied together?\u003c\/h3\u003e\n\u003cp\u003eThe two peptides act through distinct receptors — the GHRH receptor and the ghrelin receptor — that converge on the same somatotroph cell population in the anterior pituitary. In published endocrinology research, simultaneous activation of both pathways produces larger GH pulses than either compound alone, providing a useful tool for studying maximal physiological GH release.\u003c\/p\u003e\n\n\u003ch3\u003eHow is the blend supplied?\u003c\/h3\u003e\n\u003cp\u003eOptic Labs supplies CJC-1295 (no-DAC) and ipamorelin as a co-lyophilised powder in 10mg glass research vials (5mg of each component). Each vial is sealed with a tamper-evident closure. Certificates of analysis showing HPLC purity testing for each component are available on request.\u003c\/p\u003e\n\n\u003ch3\u003eHow much bacteriostatic water do I mix with a 10mg blend vial?\u003c\/h3\u003e\n\u003cp\u003eFor the 10mg combined vial, 2ml of \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e yields a 5mg\/ml total working stock (2.5mg of each peptide per ml); 5ml yields a 2mg\/ml total stock (1mg of each per ml); 1ml yields a 10mg\/ml stock (5mg of each per ml). Choose a volume based on the concentrations required by the research protocol. For a worked example, see our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003ereconstitution calculator guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eHow should the reconstituted blend be stored?\u003c\/h3\u003e\n\u003cp\u003eReconstituted CJC-1295 + ipamorelin should be stored at 2–8°C, protected from light, and used within approximately 30 days. For longer-term storage, aliquoting and freezing at −20°C or below is preferred to limit freeze-thaw degradation. Full handling protocols are covered in our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage research guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhere does Optic Labs ship to?\u003c\/h3\u003e\n\u003cp\u003eOptic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.\u003c\/p\u003e\n\n\u003ch2\u003eLegal disclaimer\u003c\/h2\u003e\n\u003cp\u003eAll products on this site are supplied for \u003cstrong\u003elaboratory research, development or analytical use only\u003c\/strong\u003e. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the \u003cstrong\u003eTherapeutic Goods Administration (TGA)\u003c\/strong\u003e or the \u003cstrong\u003eAPVMA\u003c\/strong\u003e and are not intended to diagnose, treat, cure or prevent any disease. Optic Labs is not a \u003cstrong\u003ecompounding pharmacy\u003c\/strong\u003e or manufacturing facility as defined under the \u003cem\u003eTherapeutic Goods Act 1989\u003c\/em\u003e, and is not a registered provider of scheduled medicines or therapeutic goods.\u003c\/p\u003e","brand":"Optic Labs","offers":[{"title":"Default Title","offer_id":51430831554785,"sku":null,"price":94.99,"currency_code":"AUD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0867\/4076\/2849\/files\/cjcnodacipa10_b8fecb4a-8ce2-4e95-a59d-de0a9c3ec796.png?v=1794295901"},{"product_id":"glow70-bpc-157-10mg-ghk-cu-50mg-tb-500-10mg","title":"GLOW70 (BPC-157 10mg + GHK-CU 50mg + TB-500 10mg)","description":"\u003cp\u003e\u003cstrong\u003eBuy high-purity GLOW70 stack in Australia (BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg, 70mg total). Third-party lab tested at \u0026gt;99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhat is GLOW70?\u003c\/strong\u003e GLOW70 is a ready-mixed research stack that brings together three repair-and-skin peptides — BPC-157, the copper peptide GHK-Cu, and TB-500 — in one vial. Laboratories reach for it to study angiogenesis, copper-dependent collagen and elastin synthesis, and actin-driven cell migration side by side in dermal, wound and connective-tissue models. Optic Labs supplies HPLC-tested GLOW70 (\u0026gt;99% purity for each peptide) as a co-lyophilised 70mg vial for laboratory research use only, dispatched Australia-wide from Sydney.\u003c\/p\u003e\n\n\u003ch2\u003eAbout the GLOW70 stack\u003c\/h2\u003e\n\u003cp\u003eGLOW70 is a three-compound research stack co-lyophilised in a single vial: 10mg BPC-157 (a pentadecapeptide derived from gastric juice protein BPC), 50mg GHK-Cu (a copper-binding tripeptide), and 10mg TB-500 (a 17-amino-acid fragment of thymosin β-4). The combination assembles three of the most extensively studied peptides in regenerative, dermal and connective-tissue research into a single working unit, sized to the typical mass ratios used in published animal-model and cell-culture protocols. GLOW70 is a popular tool when researchers want to examine angiogenic, copper-dependent collagen-synthesis and actin-remodelling pathways in parallel rather than across separate vials.\u003c\/p\u003e\n\u003cp\u003eOptic Labs supplies GLOW70 in Australia as a co-lyophilised powder, 70mg total, third-party HPLC verified at \u0026gt;99% purity for each constituent peptide. The stack is supplied strictly for laboratory research use only and is not intended for human consumption, clinical, cosmetic, diagnostic or veterinary application.\u003c\/p\u003e\n\n\u003ch2\u003eProduct specifications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompound:\u003c\/strong\u003e BPC-157 (10mg) + GHK-Cu (50mg) + TB-500 (10mg) co-lyophilised stack\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBPC-157:\u003c\/strong\u003e CAS 137525-51-0, ~1419.5 g\/mol, pentadecapeptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHK-Cu:\u003c\/strong\u003e CAS 49557-75-7 (peptide) \/ 89030-95-5 (copper-bound), ~340.4 g\/mol (free peptide), Gly-His-Lys with Cu\u003csup\u003e2+\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTB-500:\u003c\/strong\u003e CAS 77591-33-4, 17-amino-acid fragment of thymosin β-4\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder (co-formulated)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% by HPLC for each peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAvailable size:\u003c\/strong\u003e 70mg total per vial (10mg BPC-157 + 50mg GHK-Cu + 10mg TB-500)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrigin:\u003c\/strong\u003e Manufactured to research-grade specifications, third-party HPLC verified\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShipping:\u003c\/strong\u003e Australia-wide domestic dispatch from Sydney, NSW\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eResearch background\u003c\/h2\u003e\n\u003cp\u003eThe three peptides in GLOW70 are studied across overlapping but distinct repair and regenerative pathways. BPC-157 is characterised in the literature for angiogenic, nitric-oxide and growth-factor signalling; GHK-Cu for copper-dependent collagen synthesis, antioxidant gene expression and dermal remodelling; TB-500 for actin sequestration, cell migration and microvascular development. Combining them is a common research design when investigators want to probe parallel pathway engagement in connective-tissue, dermal and wound-healing models.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBPC-157: tendon, ligament and gastrointestinal injury models examining fibroblast outgrowth and VEGF\/eNOS signalling.\u003c\/li\u003e\n\u003cli\u003eGHK-Cu: copper-binding tripeptide research on collagen and elastin synthesis in dermal fibroblasts and ex-vivo skin models.\u003c\/li\u003e\n\u003cli\u003eGHK-Cu: gene-expression studies in cultured cells reporting modulation of antioxidant, anti-inflammatory and tissue-remodelling pathways.\u003c\/li\u003e\n\u003cli\u003eTB-500: G-actin sequestration and actin-cytoskeleton remodelling research relevant to cell migration.\u003c\/li\u003e\n\u003cli\u003eTB-500: cardiac, dermal, corneal and hair-follicle research examining endothelial and keratinocyte migration.\u003c\/li\u003e\n\u003cli\u003eCombined-peptide protocols in rodent wound and musculoskeletal-injury models examining repair time-course versus single-peptide arms.\u003c\/li\u003e\n\u003cli\u003eSkin and dermal-research designs examining whether BPC-157 + GHK-Cu + TB-500 produces additive effects on fibroblast activity and microvasculature.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor deeper background, see our \u003ca href=\"\/blogs\/news\/bpc-157-complete-research-guide-2025\"\u003eBPC-157 complete research guide\u003c\/a\u003e, our \u003ca href=\"\/blogs\/news\/ghk-cu-australia-copper-peptide-guide\"\u003eGHK-Cu copper peptide guide\u003c\/a\u003e and our \u003ca href=\"\/blogs\/news\/tb-500-australia-thymosin-injury-research-guide\"\u003eTB-500 research guide\u003c\/a\u003e. Researchers working with reconstitution should also reference our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003epeptide reconstitution guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eReconstitution and handling\u003c\/h2\u003e\n\u003cp\u003eGLOW70 is co-lyophilised — all three peptides dissolve together when the vial is reconstituted. Use sterile \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e. Adding 3mL of bacteriostatic water to a 70mg vial yields approximately 23.3mg\/mL total peptide, which corresponds to 3.33mg\/mL BPC-157, 16.67mg\/mL GHK-Cu and 3.33mg\/mL TB-500. A 5mL reconstitution gives 14mg\/mL total (2mg\/mL BPC-157, 10mg\/mL GHK-Cu, 2mg\/mL TB-500), which is often more convenient for protocols where smaller working volumes are dosed. Add diluent slowly down the side of the vial — do not inject directly onto the lyophilised cake — and allow the powder to dissolve without vigorous shaking. Reconstituted GLOW70 should be stored at 2–8°C, protected from light, and used within 30 days. For dilution maths for any working volume, see our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003epeptide reconstitution calculator guide\u003c\/a\u003e and our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eCommonly stacked research peptides\u003c\/h2\u003e\n\u003cp\u003eResearchers using GLOW70 commonly hold its constituent peptides separately for protocols requiring different ratios, alongside related repair and anti-inflammatory tools:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/bpc-157\"\u003eBPC-157\u003c\/a\u003e — single-compound vial for protocols at non-stack ratios.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/ghk-cu-50mg-100mg\"\u003eGHK-Cu\u003c\/a\u003e — single-compound copper-peptide vial for collagen and dermal-research designs.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/tb-500\"\u003eTB-500\u003c\/a\u003e — single-compound thymosin β-4 fragment vial.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/bpc-157-tb-500-10mg-20mg\"\u003eBPC-157 + TB-500 blend\u003c\/a\u003e — two-compound vial for repair-pathway research without the GHK-Cu arm.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/klow80-bpc-157-10mg-ghk-cu-50mg-tb-500-10mg-kpv-10mg\"\u003eKLOW80 stack\u003c\/a\u003e — four-compound stack adding KPV to the GLOW70 base for anti-inflammatory pathway coverage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor broader stack-design context, see our \u003ca href=\"\/blogs\/news\/peptide-research-stacks-australia-combinations\"\u003epeptide research stacks overview\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently asked questions\u003c\/h2\u003e\n\n\u003ch3\u003eIs GLOW70 legal in Australia?\u003c\/h3\u003e\n\u003cp\u003eNone of the constituent peptides — BPC-157, GHK-Cu or TB-500 — is an approved therapeutic good in Australia, and none is registered with the Therapeutic Goods Administration (TGA). Optic Labs supplies GLOW70 strictly for laboratory research, development and analytical use — not for human consumption, clinical or cosmetic application. For a detailed overview of how research peptides sit within the Australian regulatory framework, see our \u003ca href=\"\/blogs\/news\/are-peptides-legal-australia-tga-compliance-2025\"\u003eguide to peptide legality and TGA compliance in Australia\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is GLOW70?\u003c\/h3\u003e\n\u003cp\u003eGLOW70 is a co-lyophilised three-compound research stack containing 10mg BPC-157, 50mg GHK-Cu and 10mg TB-500 in a single vial. The three peptides are widely co-studied in regenerative, dermal and connective-tissue research. For background on each, see our \u003ca href=\"\/blogs\/news\/bpc-157-complete-research-guide-2025\"\u003eBPC-157\u003c\/a\u003e, \u003ca href=\"\/blogs\/news\/ghk-cu-australia-copper-peptide-guide\"\u003eGHK-Cu\u003c\/a\u003e and \u003ca href=\"\/blogs\/news\/tb-500-australia-thymosin-injury-research-guide\"\u003eTB-500\u003c\/a\u003e guides.\u003c\/p\u003e\n\n\u003ch3\u003eWhy use GLOW70 instead of three separate vials?\u003c\/h3\u003e\n\u003cp\u003eA co-lyophilised stack reduces handling steps and reconstitution events when a protocol consistently uses all three peptides together at this 1:5:1 mass ratio. For protocols that require unequal ratios, single-peptide arms or dose-escalation across one peptide, separate \u003ca href=\"\/products\/bpc-157\"\u003eBPC-157\u003c\/a\u003e, \u003ca href=\"\/products\/ghk-cu-50mg-100mg\"\u003eGHK-Cu\u003c\/a\u003e and \u003ca href=\"\/products\/tb-500\"\u003eTB-500\u003c\/a\u003e vials are the appropriate choice.\u003c\/p\u003e\n\n\u003ch3\u003eHow much bacteriostatic water do I mix with a GLOW70 vial?\u003c\/h3\u003e\n\u003cp\u003eFor a 70mg vial, 3mL of \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e yields approximately 23.3mg\/mL total peptide (3.33mg\/mL BPC-157, 16.67mg\/mL GHK-Cu, 3.33mg\/mL TB-500). 5mL gives 14mg\/mL total. See our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003ereconstitution calculator guide\u003c\/a\u003e for worked examples at other volumes.\u003c\/p\u003e\n\n\u003ch3\u003eHow should reconstituted GLOW70 be stored?\u003c\/h3\u003e\n\u003cp\u003eReconstituted GLOW70 should be stored at 2–8°C, protected from light, and used within 30 days. Lyophilised vials are stable at 2–8°C until reconstitution. For full handling guidance, see our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage research guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhere does Optic Labs ship to?\u003c\/h3\u003e\n\u003cp\u003eOptic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.\u003c\/p\u003e\n\n\u003ch2\u003eLegal disclaimer\u003c\/h2\u003e\n\u003cp\u003eAll products on this site are supplied for \u003cstrong\u003elaboratory research, development or analytical use only\u003c\/strong\u003e. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the \u003cstrong\u003eTherapeutic Goods Administration (TGA)\u003c\/strong\u003e or the \u003cstrong\u003eAPVMA\u003c\/strong\u003e and are not intended to diagnose, treat, cure or prevent any disease. Optic Labs is not a \u003cstrong\u003ecompounding pharmacy\u003c\/strong\u003e or manufacturing facility as defined under the \u003cem\u003eTherapeutic Goods Act 1989\u003c\/em\u003e, and is not a registered provider of scheduled medicines or therapeutic goods.\u003c\/p\u003e","brand":"Optic Labs","offers":[{"title":"Default Title","offer_id":51430834340065,"sku":null,"price":161.99,"currency_code":"AUD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0867\/4076\/2849\/files\/glow_270793dd-cf47-4165-b65d-be2e8a9d47e1.png?v=1794295906"},{"product_id":"klow80-bpc-157-10mg-ghk-cu-50mg-tb-500-10mg-kpv-10mg","title":"KLOW80 (BPC-157 10mg + GHK-CU 50mg + TB-500 10mg + KPV 10mg)","description":"\u003cp\u003e\u003cstrong\u003eBuy high-purity KLOW80 stack in Australia (BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg + KPV 10mg, 80mg total). Third-party lab tested at \u0026gt;99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhat is KLOW80?\u003c\/strong\u003e KLOW80 takes the three-peptide GLOW70 blend and adds KPV, giving one vial that covers four repair and inflammation pathways at once — BPC-157, the copper peptide GHK-Cu, TB-500 and the α-MSH fragment KPV. Laboratories use it to study angiogenesis, collagen synthesis, cell migration and NF-κB-linked inflammation together across wound, skin and gut models. Optic Labs supplies HPLC-tested KLOW80 (\u0026gt;99% purity for each peptide) as a co-lyophilised 80mg vial for laboratory research use only, dispatched Australia-wide from Sydney.\u003c\/p\u003e\n\n\u003ch2\u003eAbout the KLOW80 stack\u003c\/h2\u003e\n\u003cp\u003eKLOW80 is a four-compound research stack co-lyophilised in a single vial: 10mg BPC-157 (a pentadecapeptide derived from gastric juice protein BPC), 50mg GHK-Cu (a copper-binding tripeptide), 10mg TB-500 (a 17-amino-acid fragment of thymosin β-4), and 10mg KPV (an α-MSH-derived tripeptide, Lys-Pro-Val). KLOW80 extends the GLOW70 stack with KPV's anti-inflammatory and gut-barrier research profile, giving researchers a single working unit that spans angiogenic, copper-dependent collagen-synthesis, actin-remodelling and α-MSH-pathway tools. It is a frequent choice in animal-model and cell-culture research where investigators want broad coverage of repair and inflammatory pathways in parallel.\u003c\/p\u003e\n\u003cp\u003eOptic Labs supplies KLOW80 in Australia as a co-lyophilised powder, 80mg total, third-party HPLC verified at \u0026gt;99% purity for each constituent peptide. The stack is supplied strictly for laboratory research use only and is not intended for human consumption, clinical, cosmetic, diagnostic or veterinary application.\u003c\/p\u003e\n\n\u003ch2\u003eProduct specifications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompound:\u003c\/strong\u003e BPC-157 (10mg) + GHK-Cu (50mg) + TB-500 (10mg) + KPV (10mg) co-lyophilised stack\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBPC-157:\u003c\/strong\u003e CAS 137525-51-0, ~1419.5 g\/mol, pentadecapeptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHK-Cu:\u003c\/strong\u003e CAS 49557-75-7 (peptide) \/ 89030-95-5 (copper-bound), ~340.4 g\/mol (free peptide), Gly-His-Lys with Cu\u003csup\u003e2+\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTB-500:\u003c\/strong\u003e CAS 77591-33-4, 17-amino-acid fragment of thymosin β-4\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKPV:\u003c\/strong\u003e CAS 67727-97-3, ~342.4 g\/mol, Lys-Pro-Val tripeptide derived from α-MSH\u003csub\u003e(11–13)\u003c\/sub\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder (co-formulated)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% by HPLC for each peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAvailable size:\u003c\/strong\u003e 80mg total per vial (10mg BPC-157 + 50mg GHK-Cu + 10mg TB-500 + 10mg KPV)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrigin:\u003c\/strong\u003e Manufactured to research-grade specifications, third-party HPLC verified\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShipping:\u003c\/strong\u003e Australia-wide domestic dispatch from Sydney, NSW\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eResearch background\u003c\/h2\u003e\n\u003cp\u003eThe four peptides in KLOW80 cover overlapping but distinct repair and inflammatory pathways. BPC-157 is characterised in published research for angiogenic, nitric-oxide and growth-factor signalling; GHK-Cu for copper-dependent collagen synthesis and gene-expression modulation; TB-500 for actin sequestration and cell migration; KPV for α-MSH-pathway anti-inflammatory effects and gut-barrier research. Combining them allows investigators to probe parallel pathway engagement in connective-tissue, dermal, gastrointestinal and inflammation models within a single working unit.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBPC-157: tendon, ligament and gastrointestinal injury models examining VEGF\/eNOS signalling and fibroblast outgrowth.\u003c\/li\u003e\n\u003cli\u003eGHK-Cu: collagen and elastin synthesis research in dermal fibroblasts and ex-vivo skin models.\u003c\/li\u003e\n\u003cli\u003eGHK-Cu: gene-expression studies modulating antioxidant, anti-inflammatory and tissue-remodelling pathways.\u003c\/li\u003e\n\u003cli\u003eTB-500: G-actin sequestration and actin-cytoskeleton remodelling research relevant to cell migration.\u003c\/li\u003e\n\u003cli\u003eTB-500: cardiac, dermal, corneal and hair-follicle research examining endothelial and keratinocyte migration.\u003c\/li\u003e\n\u003cli\u003eKPV: α-MSH-derived tripeptide research on NF-κB modulation and pro-inflammatory cytokine attenuation in cell-culture and rodent colitis models.\u003c\/li\u003e\n\u003cli\u003eCombined-peptide protocols in models combining inflammatory and repair endpoints, where multi-pathway coverage is the design objective.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor deeper background, see our \u003ca href=\"\/blogs\/news\/bpc-157-complete-research-guide-2025\"\u003eBPC-157 complete research guide\u003c\/a\u003e, our \u003ca href=\"\/blogs\/news\/ghk-cu-australia-copper-peptide-guide\"\u003eGHK-Cu copper peptide guide\u003c\/a\u003e, our \u003ca href=\"\/blogs\/news\/tb-500-australia-thymosin-injury-research-guide\"\u003eTB-500 research guide\u003c\/a\u003e and our \u003ca href=\"\/blogs\/news\/kpv-peptide-australia-anti-inflammatory-research\"\u003eKPV anti-inflammatory research guide\u003c\/a\u003e. Researchers working with reconstitution should also reference our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003epeptide reconstitution guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eReconstitution and handling\u003c\/h2\u003e\n\u003cp\u003eKLOW80 is co-lyophilised — all four peptides dissolve together when the vial is reconstituted. Use sterile \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e. Adding 4mL of bacteriostatic water to an 80mg vial yields 20mg\/mL total peptide, which corresponds to 2.5mg\/mL BPC-157, 12.5mg\/mL GHK-Cu, 2.5mg\/mL TB-500 and 2.5mg\/mL KPV. A 5mL reconstitution gives 16mg\/mL total (2mg\/mL BPC-157, 10mg\/mL GHK-Cu, 2mg\/mL TB-500, 2mg\/mL KPV). Add diluent slowly down the side of the vial — do not inject directly onto the lyophilised cake — and allow the powder to dissolve without vigorous shaking. Reconstituted KLOW80 should be stored at 2–8°C, protected from light, and used within 30 days. For dilution maths for any working volume, see our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003epeptide reconstitution calculator guide\u003c\/a\u003e and our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eCommonly stacked research peptides\u003c\/h2\u003e\n\u003cp\u003eResearchers using KLOW80 commonly hold its constituent peptides separately for protocols requiring different ratios or single-compound arms:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/bpc-157\"\u003eBPC-157\u003c\/a\u003e — single-compound vial for protocols at non-stack ratios.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/ghk-cu-50mg-100mg\"\u003eGHK-Cu\u003c\/a\u003e — single-compound copper-peptide vial.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/tb-500\"\u003eTB-500\u003c\/a\u003e — single-compound thymosin β-4 fragment vial.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/kpv-10mg\"\u003eKPV\u003c\/a\u003e — single-compound α-MSH-derived tripeptide for anti-inflammatory and gut-barrier research.\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/products\/glow70-bpc-157-10mg-ghk-cu-50mg-tb-500-10mg\"\u003eGLOW70 stack\u003c\/a\u003e — three-compound version of KLOW80 without the KPV arm.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor broader stack-design context, see our \u003ca href=\"\/blogs\/news\/peptide-research-stacks-australia-combinations\"\u003epeptide research stacks overview\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently asked questions\u003c\/h2\u003e\n\n\u003ch3\u003eIs KLOW80 legal in Australia?\u003c\/h3\u003e\n\u003cp\u003eNone of the constituent peptides — BPC-157, GHK-Cu, TB-500 or KPV — is an approved therapeutic good in Australia, and none is registered with the Therapeutic Goods Administration (TGA). Optic Labs supplies KLOW80 strictly for laboratory research, development and analytical use — not for human consumption, clinical or cosmetic application. For a detailed overview of how research peptides sit within the Australian regulatory framework, see our \u003ca href=\"\/blogs\/news\/are-peptides-legal-australia-tga-compliance-2025\"\u003eguide to peptide legality and TGA compliance in Australia\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhat is KLOW80?\u003c\/h3\u003e\n\u003cp\u003eKLOW80 is a co-lyophilised four-compound research stack containing 10mg BPC-157, 50mg GHK-Cu, 10mg TB-500 and 10mg KPV in a single vial. The four peptides are co-studied in repair, dermal, gastrointestinal and inflammation research. For background on each, see our \u003ca href=\"\/blogs\/news\/bpc-157-complete-research-guide-2025\"\u003eBPC-157\u003c\/a\u003e, \u003ca href=\"\/blogs\/news\/ghk-cu-australia-copper-peptide-guide\"\u003eGHK-Cu\u003c\/a\u003e, \u003ca href=\"\/blogs\/news\/tb-500-australia-thymosin-injury-research-guide\"\u003eTB-500\u003c\/a\u003e and \u003ca href=\"\/blogs\/news\/kpv-peptide-australia-anti-inflammatory-research\"\u003eKPV\u003c\/a\u003e guides.\u003c\/p\u003e\n\n\u003ch3\u003eHow does KLOW80 differ from GLOW70?\u003c\/h3\u003e\n\u003cp\u003eKLOW80 is essentially the GLOW70 stack with an additional 10mg of KPV added to the same vial. Researchers who want anti-inflammatory and gut-barrier pathway coverage alongside the angiogenic, copper-dependent collagen-synthesis and actin-remodelling tools of GLOW70 typically reach for KLOW80; researchers running designs without an inflammation arm typically use \u003ca href=\"\/products\/glow70-bpc-157-10mg-ghk-cu-50mg-tb-500-10mg\"\u003eGLOW70\u003c\/a\u003e instead.\u003c\/p\u003e\n\n\u003ch3\u003eHow much bacteriostatic water do I mix with a KLOW80 vial?\u003c\/h3\u003e\n\u003cp\u003eFor an 80mg vial, 4mL of \u003ca href=\"\/products\/bac-water-3ml-10ml\"\u003ebacteriostatic water\u003c\/a\u003e yields 20mg\/mL total peptide (2.5mg\/mL BPC-157, 12.5mg\/mL GHK-Cu, 2.5mg\/mL TB-500, 2.5mg\/mL KPV). 5mL gives 16mg\/mL total. See our \u003ca href=\"\/blogs\/news\/peptide-reconstitution-calculator-guide-australia\"\u003ereconstitution calculator guide\u003c\/a\u003e for worked examples at other volumes.\u003c\/p\u003e\n\n\u003ch3\u003eHow should reconstituted KLOW80 be stored?\u003c\/h3\u003e\n\u003cp\u003eReconstituted KLOW80 should be stored at 2–8°C, protected from light, and used within 30 days. Lyophilised vials are stable at 2–8°C until reconstitution. For full handling guidance, see our \u003ca href=\"\/blogs\/news\/peptide-storage-complete-research-guide\"\u003epeptide storage research guide\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eWhere does Optic Labs ship to?\u003c\/h3\u003e\n\u003cp\u003eOptic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.\u003c\/p\u003e\n\n\u003ch2\u003eLegal disclaimer\u003c\/h2\u003e\n\u003cp\u003eAll products on this site are supplied for \u003cstrong\u003elaboratory research, development or analytical use only\u003c\/strong\u003e. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the \u003cstrong\u003eTherapeutic Goods Administration (TGA)\u003c\/strong\u003e or the \u003cstrong\u003eAPVMA\u003c\/strong\u003e and are not intended to diagnose, treat, cure or prevent any disease. Optic Labs is not a \u003cstrong\u003ecompounding pharmacy\u003c\/strong\u003e or manufacturing facility as defined under the \u003cem\u003eTherapeutic Goods Act 1989\u003c\/em\u003e, and is not a registered provider of scheduled medicines or therapeutic goods.\u003c\/p\u003e","brand":"Optic Labs","offers":[{"title":"Default Title","offer_id":51430837453025,"sku":null,"price":180.99,"currency_code":"AUD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0867\/4076\/2849\/files\/klow_2e301683-3a56-4d55-8137-0d8348284b8e.png?v=1794295909"}],"url":"https:\/\/opticlabsaus.com\/collections\/peptide-blends.oembed","provider":"Optic Labs","version":"1.0","type":"link"}